Gaurav Sutrave
YOU?
Author Swipe
View article: 423 | ctDNA‐DIRECTED INTERVENTION WITH EPCORITAMAB ALONE OR IN COMBINATION WITH LENALIDOMIDE‐RITUXIMAB IS FEASIBLE IN THE EARLY POST‐CAR‐T POPULATION AT HIGH RISK OF RELAPSE
423 | ctDNA‐DIRECTED INTERVENTION WITH EPCORITAMAB ALONE OR IN COMBINATION WITH LENALIDOMIDE‐RITUXIMAB IS FEASIBLE IN THE EARLY POST‐CAR‐T POPULATION AT HIGH RISK OF RELAPSE Open
View article: Early Stage Professionals Committee proceedings from the International Society for Cell & Gene Therapy 2022 Annual Meeting
Early Stage Professionals Committee proceedings from the International Society for Cell & Gene Therapy 2022 Annual Meeting Open
View article: Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant
Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant Open
Virus-specific T-cells (VSTs) from third-party donors mediate short- and long-term antiviral effects in allogeneic hematopoietic stem cell transplant (HSCT) recipients with relapsed or refractory viral infections. We investigated early adm…
View article: Combining <scp>CD34</scp>+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant
Combining <span>CD34</span>+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant Open
We designed a trial to simultaneously address the problems of graft versus host disease (GVHD), infection, and recurrence of malignancy after allogeneic stem cell transplantation. CD34 + stem cell isolation was used to minimize the develop…
View article: Characterizing piggyBat—a transposase for genetic modification of T cells
Characterizing piggyBat—a transposase for genetic modification of T cells Open
View article: Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with<i>piggyBac</i>-modified CD19 CAR T cells
Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with<i>piggyBac</i>-modified CD19 CAR T cells Open
View article: Investigation of product-derived lymphoma following infusion of <i>piggyBac</i>-modified CD19 chimeric antigen receptor T cells
Investigation of product-derived lymphoma following infusion of <i>piggyBac</i>-modified CD19 chimeric antigen receptor T cells Open
We performed a phase 1 clinical trial to evaluate outcomes in patients receiving donor-derived CD19-specific chimeric antigen receptor (CAR) T cells for B-cell malignancy that relapsed or persisted after matched related allogeneic hemopoie…
View article: <i>Anncaliia algerae</i> Microsporidial Myositis, New South Wales, Australia
<i>Anncaliia algerae</i> Microsporidial Myositis, New South Wales, Australia Open
We describe the successful management of Anncaliia algerae microsporidial myositis in a man with graft versus host disease after hemopoietic stem cell transplantation. We also summarize clinical presentation and management approaches and d…
View article: Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells
Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells Open
Key Points Partially HLA-matched third-party CMV-specific T cells provide long-term viral control in HSCT patients with resistant CMV infection. Viral control occurs in the setting of recovery of CD8+ terminally differentiated effector T c…